-
3 weeks ago | 
medicalnewstoday.com | Paul Ian Cross
Share on PinterestA novel treatment for hard-to-control high blood pressure has shown strong results in a major global clinical trial. The Phase 3 Launch-HTN study found that lorundrostat, an aldosterone synthase inhibitor, safely and consistently lowered blood pressure in a large, diverse group of patients who had not responded to other medications. These findings mark a significant step forward in the development of the first targeted aldosterone synthase inhibitor for these conditions.
-
3 weeks ago | 
aol.com | Paul Ian Cross
A novel treatment for hard-to-control high blood pressure has shown strong results in a major global clinical trial. The Phase 3 Launch-HTN study found that lorundrostat, an aldosterone synthase inhibitor, safely and consistently lowered blood pressure in a large, diverse group of patients who had not responded to other medications. These findings mark a significant step forward in the development of the first targeted aldosterone synthase inhibitor for these conditions.
-
3 weeks ago | 
resources.healthgrades.com | Paul Ian Cross
A novel treatment for hard-to-control high blood pressure has shown strong results in a major global clinical trial. The Phase 3 Launch-HTN study found that lorundrostat, an aldosterone synthase inhibitor, safely and consistently lowered blood pressure in a large, diverse group of patients who had not responded to other medications. These findings mark a significant step forward in the development of the first targeted aldosterone synthase inhibitor for these conditions.
-
1 month ago | 
medicalnewstoday.com | Paul Ian Cross
Share on PinterestA new study from UC San Francisco may offer the first clear biological markers for frontotemporal dementia, a condition that often affects people in midlife and is difficult to diagnose. By analysing spinal fluid from patients with inherited frontotemporal dementia, researchers uncovered protein changes linked to RNA regulation and brain connectivity; early indicators that could lead to earlier, more accurate diagnosis.
-
1 month ago | 
resources.healthgrades.com | Paul Ian Cross
A new study from UC San Francisco may offer the first clear biological markers for frontotemporal dementia, a condition that often affects people in midlife and is difficult to diagnose. By analysing spinal fluid from patients with inherited frontotemporal dementia, researchers uncovered protein changes linked to RNA regulation and brain connectivity; early indicators that could lead to earlier, more accurate diagnosis.
-
1 month ago | 
medicalnewstoday.com | Paul Ian Cross
Share on PinterestResearchers at UVA Health have found that a class of HIV drugs called nucleotide reverse transcriptase inhibitors (NRTIs) may significantly reduce the risk of developing Alzheimer’s disease. Their large-scale analysis of United States health insurance data revealed that patients taking these medications had up to a 13% lower risk of Alzheimer’s disease each year.
-
1 month ago | 
resources.healthgrades.com | Paul Ian Cross
Researchers at UVA Health have found that a class of HIV drugs called nucleotide reverse transcriptase inhibitors (NRTIs) may significantly reduce the risk of developing Alzheimer’s disease. Their large-scale analysis of United States health insurance data revealed that patients taking these medications had up to a 13% lower risk of Alzheimer’s disease each year. Based on these findings, the team is calling for clinical trials to test whether these drugs could be used to help prevent Alzheimer’s.
-
1 month ago | 
medicalnewstoday.com | Paul Ian Cross
Share on PinterestEarly detection of prostate cancer remains a major clinical challenge due to the lack of reliable biomarkers, despite the disease being highly treatable when caught in its early stages. Now, researchers have identified a new set of urine-based biomarkers that can accurately detect both the presence and severity of prostate cancer. The study combines artificial intelligence with detailed genetic analysis and could potentially offer an alternative to current PSA testing.
-
2 months ago | 
medicalnewstoday.com | Paul Ian Cross
Share on PinterestAccording to a new study, a once-weekly dose of tirzepatide can lead to significant, sustained weight loss for up to 3 years in adults with overweight or obesity who do not have diabetes. The findings build on earlier results from the SURMOUNT-1 trial and suggest that treatment responses may vary based on factors such as sex and the presence of obesity-related conditions. Researchers also identified patterns in how participants lost weight over time.
-
2 months ago | 
medicalnewstoday.com | Paul Ian Cross
Share on PinterestGLP-1 drugs have helped people successfully achieve and maintain weight loss; however, losing muscle has been a significant concern. New research suggests that weight loss treatments using GLP-1 and dual GLP-1/GIP receptor agonists can lead to significant fat loss while still maintaining lean muscle mass. The study found that strength training and enough protein were key to keeping muscle while losing weight, as well as getting guidance from an obesity medicine specialist.
